Article Text

Download PDFPDF
Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response
  1. Gonzalo Tapia Rico1,2,
  2. Amanda Townsend1,2,
  3. Timothy Price1,2 and
  4. Kevin Patterson1
  1. 1Medical Oncology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia
  2. 2The University of Adelaide, School of Medicine, Adelaide, South Australia, Australia
  1. Correspondence to Dr Gonzalo Tapia Rico; gonzalo.tapiarico{at}


Myxopapillary ependymoma (MPE) is a rare glial tumour mainly located in the areas of the conus medullaris, cauda equina and filum terminale of the spinal cord. Ectopic MPE tends to behave more aggressively and distant metastases are often seen. Unfortunately, no standard treatment options are established as only small series of treated patients and a few reported cases are available in the literature. We report the case of a 25-year-old woman who was initially diagnosed with a metastatic MPE, with multiple bilateral lung metastases. She was treated with an investigational monoclonal antibody antiprogrammed cell death protein 1, called tislelizumab (BGB-A317), following surgical resection of the perisacral primary mass. The response was long-lasting and side effects nil. Immunotherapy is a treatment modality to be considered in patients with rare tumours.

  • cancer intervention
  • immunological products and vaccines
  • neurooncology
  • CNS cancer
  • neurosurgery

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors GTR contributed in drafting manuscript as well as literature search; AT, TP and KP contributed to literature search and critical reviews. All authors reviewed and approved the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.